In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in the risk of ESKD (7 vs 20 events, HR 0.35, p=0.02) persisted after 9.9 years of overall follow-up (29 vs 53 events, HR 0.54, p<0.01). These effects were greater in earlier stage CKD (p=0.04) and at lower baseline systolic blood pressure levels (p=0.01). The effects of glucose lowering on the risks of death, CV death or major CV events did not differ by levels of kidney function (p>0.26).
Conclusions: Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of CV events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure.
(ADVANCE-ON Clinical Trials.gov NCT00949286)
Diabetes mellitus has surpassed glomerulonephritis as the commonest cause of end stage kidney disease (ESKD) in the developed world, and many developing countries (1) . Although only a minority of individuals with diabetes will develop nephropathy and ESKD, the rapidly increasing number of people with type 2 diabetes is projected to result in a substantial increase in the numbers requiring renal replacement therapy, in turn leading to major growth in economic costs for health systems (2) . In addition, CKD is recognized as one of the strongest risk factors for cardiovascular disease, particularly in the presence of diabetes, conferring a substantial increase in the risk of death and hospitalization (3) .
Despite the implementation of 'best practice' standards of care for lifestyle modification, blood pressure lowering and renin-angiotensin-aldosterone system (RAAS) blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4, 5) .
Although a number of promising novel therapies are being studied in early clinical trials, none are as yet available (6) . This has resulted in renewed interest in the role of intensive glucose control. Post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) cohort of newly diagnosed patients with type 2 diabetes (7) and the Diabetes Control and Complications Trial (DCCT) cohort of young patients with type 1 diabetes (8), showed a sustained benefit for microvascular complications, beyond the period of intensive glucose control. In these studies, microvascular complications were composites of retinal photocoagulation, microalbuminuria, and neuropathy with few, if any, patients developing ESKD or dying from renal disease (9).
We have previously reported, in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study, that intensive glucose control in patients with type 2 diabetes significantly reduced the risk of a range of renal outcomes including new or worsening nephropathy and ESKD (10) . However, the small number of ESKD events observed during the trial limited the strength of the conclusions. In addition, the safety of intensive glucose control in the presence of CKD has been questioned, with the ACCORD trial (11) recently reporting that its intensive glucose lowering strategy increased the risk of cardiovascular and all-cause death among participants with CKD, but not in those with normal kidney function.
The outcomes of the 6-year post-trial follow-up of the ADVANCE trial cohort, also known as the ADVANCE-ObservatioNal study (ADVANCE-ON), were recently published (12). Here we report on further analyses that examine the long-term effects of the intensive glucose control strategy on ESKD, CV events and death, including analyses across different levels of kidney function, in patients with type 2 diabetes.
Research Design and Methods

ADVANCE trial
The original trial design and methods have been published previously (13, 14) . Briefly, February 2014, patients attending visits in person (whether or not they had completed assessment at the first visit) were invited to undergo re-assessment of HbA1c, fasting blood glucose, weight, blood pressure, serum creatinine and urinary albumin:creatinine ratio.
Study outcomes
The pre-specified renal outcomes for ADVANCE-ON were ESKD (requirement for dialysis or renal transplantation) and death due to renal disease. Other outcomes included death due to any cause, major cardiovascular events (myocardial infarction, stroke or cardiovascular death, examined jointly and separately), and major hypoglycemia. It was not possible to replicate the outcome "new or worsening nephropathy" as defined in the original trial (development of macroalbuminuria (UACR>300μg/mg or 33.9mg/mmol/L), doubling of serum creatinine to a level of 200μmol/L (2.26mg/dl), ESKD and death due to renal disease because levels of serum creatinine and urinary albumin were only measured in a subgroup of patients during post-trial follow-up. Outcomes occurring during post-trial follow-up were as reported by the study centers using the standardized definitions used during the trial, without central adjudication.
Statistical methods
Analyses were conducted according to the initial treatment assignment. Treatment effects were examined using cumulative incidence survival curves and Cox proportional hazards models. Patients were censored at the first relevant end-point, the date of death, date of last visit (for those still alive) or date last known to be alive for those whose vital status was unknown at the end of the study (February 28, 2014) . Hazard ratios were estimated for the intrial period and over the entire period of follow-up. An additional post-hoc observational analysis was performed for the post-trial period alone. Serial hazard ratios (HRs) with 95% confidence intervals (CI) were estimated at the end of each calendar year of post-trial followup. The homogeneity of treatment effects for pre-specified subgroups was tested by adding an interaction term to the relevant Cox models.
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate the eGFR. For analyses by baseline CKD status, participants were divided into CKD stage 1 (eGFR ≥90 ml/min/1.73m 2 and urine albumin/creatinine ratio ≥30 mg/mg);
CKD stage 2 (eGFR between 60 and 89 ml/min/1.73m 2 and urine albumin/creatinine ratio ≥30 mg/mg), CKD Stage ≥ 3 (eGFR less than 60 ml/min/1.73m 2 with or without albuminuria, and those without CKD (eGFR ≥60 ml/min/1.73m 2 and urine albumin/creatinine ratio <30 mg/mg) (16) .
The analyses were performed with SAS (version 9.2). All tests were two-sided and p values less than 0.05 were considered to indicate statistical significance. The protocol pre-specified that no adjustments would be made for the multiple statistical testing (12) . In light of this the findings were interpreted with the appropriate degree of caution.
Results
Of 10,082 patients originally assigned to the randomized treatments and alive at the end of Tables S1-S3 ). The use of blood pressure lowering agents, statins and anti-platelet agents was also comparable across the groups, irrespective of the CKD stage (Supplementary Tables S1-S3 ).
Glycemic control
The mean difference in HbA1c (0.67% 95%CI 0.64, 0.70, p<0.001) observed at the end of randomized therapy was lost when measured on average 2.9 years later at the first post-trial visit (0.08%, 95%CI -0.07, 0.22, p=0.29). There was a rise in HbA1c in the intensive control group approaching that observed in the standard control group. The HbA1c levels of the two groups converged at the first post-trial visit (7.3% vs 7.3%, p=0.29) and remained similar at the last post-trial visit (12) .
ESKD or Renal Death
During the in-trial period, 27 patients recorded ESKD events and 37 patients died due to renal causes. During the post-trial period an additional 55 patients recorded ESKD events and 64 patients died due to renal causes ( Table 1 The non-significant effect on the risk of death due to renal disease observed during the in trial period (HR 0.85, 95%CI 0.45 to 1.62) remained similar after a total of 9.9 years of follow-up (HR 0.89, 95%CI 0.60 to 1.31) (Figure 1 ).
Absolute renal effects
Across the entire population over 9.9 years, 194 participants would need to be treated with intensive glucose control to prevent one ESKD event (Table 1) . Further, the NNT by CKD stage was 109 for CKD stage 1 and 2 and 393 for CKD stage 3 or greater. The NNT by SBP was 120 for baseline SBP less than 140mmHg and 368 for baseline SBP ≥140mmHg (Table 1) .
Other outcomes
The rate of major hypoglycemia was low overall and the increase in risk for the intensive versus the standard glucose control group observed during the trial was no longer evident after post-trial follow-up (Supplementary figure 2) . The absolute risk of hypoglycemia tended to be slightly higher for the group with CKD Stage 3 or greater as compared to no CKD or CKD stage 1 and 2 irrespective of the original randomized groups. However, the increase in risk for the intensive versus standard glucose control groups was similarly no longer evident for subgroups of patients defined by CKD stage after post-trial follow-up (overall study period p for heterogeneity 0.92).
Intensive glucose control had no clear effects on overall all-cause mortality, cardiovascular death, major cardiovascular events, myocardial infarction or stroke. In addition, there was no evidence that baseline CKD status had any impact on the effect of intensive glucose control on these outcomes (Figure 3 , all p-heterogeneity >0.2) during the in-trial period or during extended follow-up.
Conclusions
After following the ADVANCE trial cohort for a total of 9.9 years, we show that a prior period of intensive glucose control continues to protect against the development of ESKD in patients with type 2 diabetes. The patients who appear to benefit the most are those with preserved kidney function, with intermediate effects in the group with CKD stage 1 or 2, and lesser effects in participants with CKD stage 3 or greater at baseline. Greater reductions in ESKD were also observed in participants with better blood pressure control at baseline (systolic BP <140mmHg). Importantly, the impact of intensive glucose control on mortality or major cardiovascular events was not adversely affected by CKD at baseline, either during the trial or overall study follow-up.
Our data provide the strongest evidence to date regarding the renal benefits of intensive glucose lowering, and are consistent with data on intermediate outcomes from other studies.
These include the Epidemiology of Diabetes Interventions and Control (EDIC) study in a population of younger individuals with type 1 diabetes, which reported that a prior period of intensive glucose control reduced the long-term risk of developing renal impairment (eGFR below 60ml/min/1.73m 2 ) by 50% after a median follow-up of 22 years (18) . However, in that study a clear benefit for ESKD was not demonstrated, most likely because few ESKD events were recorded. Similarly the long-term follow-up of the UKPDS cohort of newly diagnosed patients with type 2 diabetes reported persistent microvascular (eye and renal events) and emerging macrovascular benefits in those previously assigned to intensive glucose lowering, with benefits for kidney failure defined by lower risk of increases in serum creatinine to more than 250 μmol/L. The ACCORD study reported a numerically lower risk of renal failure with intensive glucose lowering, however this did not achieve statistical significance (19) . The results regarding the effects on ESKD in the long-term follow-up of the ACCORD trial are awaited with interest.
In ADVANCE the difference in the rate of ESKD events between the intensive and the standard glucose control groups took more than 2 years to emerge, but then persisted (with a further numerically lower number of events) to the end of the overall study period, even after the HbA1c converged. The risk reduction for ESKD events observed in ADVANCE-ON likely goes beyond a simple carry forward of the effects observed during the original trial period. As the development of ESKD often takes decades to appear after the onset of diabetes mellitus, it might well be anticipated that slowing of this process would take years to become evident especially if it requires abrogation of diabetes-induced structural changes in the glomerulus (20, 21) In contrast, the effects of RAS blockade and BP lowering are likely to have a more rapid onset and offset in response to treatment.
Our results highlight the importance of commencing intensive glucose control before diabetic kidney disease develops as lesser renal benefit was observed in participants with an established reduction in kidney function, suggesting that the relative contribution of glucose dependent and glucose independent pathways may vary at different levels of kidney function.
The lesser benefit in those with moderately reduced kidney function (CKD stage 3 or greater) may indicate that glucose independent mechanisms of renal progression are predominant, in the later stages of the disease (22) . In the subgroup of patients without baseline CKD the benefits for ESKD were maintained in the long-term suggesting the earlier period of intensive glucose control may have prevented structural changes in both the glomeruli and tubulointerstitium when renal function was relatively intact.
Similar differences were found in subgroups defined by baseline BP, with a much greater reduction in ESKD by the end of overall follow-up in participants whose systolic BP at baseline was below the hypertensive range (<140mmHg). These findings also support the premise that greater benefits will be obtained through intensive glucose control earlier in the life course of the patient with type 2 diabetes. While a recent report has raised concerns regarding a possible increase in the risk of adverse outcomes in the presence of CKD with intensive glucose control, particularly risk of death (11), we found no evidence for this.
Collectively, these data support early intensive glucose control and optimal blood pressure levels for the prevention of long-term renal complications in individuals with type 2 diabetes.
An interesting finding was the lack of consistency in the results for ESKD and renal death. A low number of events is one reason. Death purely attributed to renal causes is less common than death due to cardiovascular or cerebrovascular causes. However, establishing cause of death during any clinical trial may be challenging. During the ADVANCE trial renal death was adjudicated whereas during the ADVANCE-ON post-trial follow-up renal death could not be adjudicated. In addition, it may be difficult to ascertain whether a death is due to progressive kidney failure, inter-current cardiovascular event, or some combination of the two. This could result in greater uncertainty as to the effects on this outcome as compared to that of ESKD, which is simpler to define as requirement for dialysis or renal transplantation.
Indeed other clinical trials such as RENAAL and IDNT have similarly not been able to identify beneficial effects on renal death (4, 5) It was also not possible to report progression or regression of albuminuria or doubling of serum creatinine as occurred in the original trial because serum creatinine levels and urinary albumin-to-creatinine ratios at the first post-trial visit were only available and able to be collected for a subset of participants (13) .
A clear strength of this study is the long-term follow-up of a large and diverse patient population with type 2 diabetes. The limitations include non-adjudicated renal endpoints and the lack of complete biochemical data for all participants during the post-trial follow-up.
Additionally, although the number of ESKD events tripled during the post-trial period, the number of events remained small. This limitation is especially important to bear in mind when interpreting differences between subgroups and between stages of CKD.
Our data build on a growing body of evidence indicating an important role for intensive glucose control in limiting the progression of kidney disease and in curbing the growing number of patients around the world with type 2 diabetes requiring dialysis or transplantation as a result of diabetic kidney disease. 
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